Feasibility of Subcutaneous Immunoglobulin Therapy as the Maintenance Therapy in Patients with Autoimmune Neuromuscular Disease: A Prospective Study

Long-term immunoglobulin therapy is crucial for several neuromuscular disorders (NMD). Recently, subcutaneous immunoglobulin (SCIg) has become an alternate to intravenous immunoglobulin (IVIg) for maintenance therapy to address limitations. This prospective study assessed the feasibility of SCIg as maintenance therapy for various NMDs after transitioning from IVIg. Overall, the mean monthly immunoglobulin dose remained stable or reduced after transition while maintaining efficacy. Participants reported significantly fewer side effects (29.2 % vs. 66.7%) with SCIg. Compliance with self-infusion and dosing regimen with SCIg was high, with no product wastage. The study shows SCIg therapy has distinct advantages over IVIg and should be considered for NMD patients requiring maintenance therapy.